both vaccines.2,3 Studies have demonstrated fatigue, headache, myalgia, and nausea as potential adverse reactions without systemic cutaneous adverse effects, similar to the results of previous mRNA vaccines.2,3
If further adverse systemic reaction were to emerge following vaccination, dermatologists have an important duty to report observations to the Vaccine Adverse Event Reporting System (VAERS) to enhance continuous safety monitoring. As efforts to expand US COVID-19 vaccinations continue, dermatologists are ideally positioned to reassure patients experiencing common cutaneous injection site reactions and educate and encourage those who are hesitant to accept these important preventative vaccines. Greater knowledge of potential adverse effects may increase public confidence for those who may be wary of new vaccine technologies.
If further adverse systemic reaction were to emerge following vaccination, dermatologists have an important duty to report observations to the Vaccine Adverse Event Reporting System (VAERS) to enhance continuous safety monitoring. As efforts to expand US COVID-19 vaccinations continue, dermatologists are ideally positioned to reassure patients experiencing common cutaneous injection site reactions and educate and encourage those who are hesitant to accept these important preventative vaccines. Greater knowledge of potential adverse effects may increase public confidence for those who may be wary of new vaccine technologies.
DISCLOSURES
Dr. Dellavalle is a Joint Coordinating Editor for Cochrane Skin, a dermatology section editor for UpToDate, a Social Media Editor for the Journal of the American Academy of Dermatology (JAAD), and a Podcast Editor for the Journal of Investigative Dermatology (JID). He is a coordinating editor representative on Cochrane Council.
Financial Disclosure: Dr. Dellavalle receives editorial stipends (JID), royalties (UpToDate), and expense reimbursement from Cochrane Skin.
Financial Disclosure: Dr. Dellavalle receives editorial stipends (JID), royalties (UpToDate), and expense reimbursement from Cochrane Skin.
REFERENCES
1. COVID-19 Cases, Deaths, and Trends in the US | CDC COVID Data Tracker. CDC. Accessed December 21, 2020. https://covid.cdc.gov/covid-data-tracker
2. Pfizer-BioNTech COVID-19 Vaccine. FDA. Published online December 18, 2020. Accessed December 21, 2020. https://www.fda.gov/emergency-preparedness- and-response/coronavirus-disease-2019-covid-19/pfizer-biontechcovid- 19-vaccine 3. Moderna COVID-19 Vaccine. FDA. Published online December 18, 2020. Accessed December 21, 2020. https://www.fda.gov/emergency-preparednessand- response/coronavirus-disease-2019-covid-19/moderna-covid-19-vaccine
4. COVID-19 and Your Health. CDC. Accessed December 21, 2020. https:// www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/mrna.html
5. Feldman RA, Fuhr R, Smolenov I, et al. mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials. Vaccine. 2019;37(25):3326-3334. doi:10.1016/j.vaccine.2019.04.074
6. Moderna Highlights Opportunity of mRNA Vaccines at its First Vaccines Day. Published April 14, 2020. Accessed December 21, 2020. https://www. businesswire.com/news/home/20200414005276/en/Moderna-Highlights- Opportunity-of-mRNA-Vaccines-at-its-First-Vaccines-Day
7. Alberer M, Gnad-Vogt U, Hong HS, et al. Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial. Lancet Lond Engl. 2017;390(10101):1511-1520. doi:10.1016/S0140-6736(17)31665-3
8. Moderna Announces Additional Positive Phase 1 Data from Cytomegalovirus (CMV) Vaccine (mRNA-1647) and First Participant Dosed in Phase 2 Study | Moderna, Inc. Accessed December 21, 2020. https://investors.modernatx. com/news-releases/news-
2. Pfizer-BioNTech COVID-19 Vaccine. FDA. Published online December 18, 2020. Accessed December 21, 2020. https://www.fda.gov/emergency-preparedness- and-response/coronavirus-disease-2019-covid-19/pfizer-biontechcovid- 19-vaccine 3. Moderna COVID-19 Vaccine. FDA. Published online December 18, 2020. Accessed December 21, 2020. https://www.fda.gov/emergency-preparednessand- response/coronavirus-disease-2019-covid-19/moderna-covid-19-vaccine
4. COVID-19 and Your Health. CDC. Accessed December 21, 2020. https:// www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/mrna.html
5. Feldman RA, Fuhr R, Smolenov I, et al. mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials. Vaccine. 2019;37(25):3326-3334. doi:10.1016/j.vaccine.2019.04.074
6. Moderna Highlights Opportunity of mRNA Vaccines at its First Vaccines Day. Published April 14, 2020. Accessed December 21, 2020. https://www. businesswire.com/news/home/20200414005276/en/Moderna-Highlights- Opportunity-of-mRNA-Vaccines-at-its-First-Vaccines-Day
7. Alberer M, Gnad-Vogt U, Hong HS, et al. Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial. Lancet Lond Engl. 2017;390(10101):1511-1520. doi:10.1016/S0140-6736(17)31665-3
8. Moderna Announces Additional Positive Phase 1 Data from Cytomegalovirus (CMV) Vaccine (mRNA-1647) and First Participant Dosed in Phase 2 Study | Moderna, Inc. Accessed December 21, 2020. https://investors.modernatx. com/news-releases/news-
AUTHOR CORRESPONDENCE
Robert P. Dellavalle MD PhD MPH robert.dellavalle@cuanschutz.edu
